Literature DB >> 22946682

Life-style and metformin for the prevention of endometrial pathology in postmenopausal women.

Carlo Campagnoli1, Chiara Abbà, Simona Ambroggio, Tiziana Brucato, Patrizia Pasanisi.   

Abstract

In western women, the endometrium is frequently exposed, even after menopause, to the endogenous hormonal stimulation. Such a stimulation increases the risk of pathologic conditions such as endometrial hyperplasia and type I (endometrioid) endometrial adenocarcinoma. Metabolic syndrome, obesity, insulin resistance and type II diabetes promote the endometrial stimulation, and are recognized risk factors for endometrial cancer. Furthermore, chronic hyperinsulinemia linked both to obesity and metabolic syndrome influences endometrial proliferation through direct and indirect actions. Intentional weight loss, calorie restriction and physical activity are associated with a reduced risk of the endometrial pathology. Biological mechanisms include reduction in insulin and sex steroid hormone levels. In addition to life-style modifications, the antidiabetic metformin may be proposed as preventive agent. Metformin reduces the metabolic syndrome, lowers insulin and testosterone levels in postmenopausal women, and it is a potent inhibitor of endometrial cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946682     DOI: 10.3109/09513590.2012.706671

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  4 in total

1.  Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.

Authors:  Haruko Irie; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kanako Nakamura; Kiyoko Umene; Yuya Nogami; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

2.  Long-term alcohol intake and risk of endometrial cancer in the Nurses' Health Study, 1980-2010.

Authors:  Y Je; I De Vivo; E Giovannucci
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

3.  Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Chao Gu; Chengcheng Ning; Xuezhen Luo; Qiongjie Zhou; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

4.  Metformin-Treatment Option for Social Impairment? An Open Clinical Trial to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior.

Authors:  Benedikt Gasser; Johann Kurz; Samuel Buerki; Markus Mohaupt
Journal:  Life (Basel)       Date:  2022-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.